Piper Sandler analyst Joseph Catanzaro raised the firm’s price target on Biomea Fusion (BMEA) to $19 from $10 and keeps an Overweight rating on the shares. The firm notes Biomea reported Q3 earnings and provided a pipeline update. Most notably, Biomea is now specifically guiding towards Phase II topline readouts in both T2D and T1D in December.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: